Liver cancer ranks fifth in frequency and third in mortality, with estimated numbers of over 700,000 new cases every year worldwide. Hepatocellular carcinoma (HCC) is the most common form of liver cancer that originates from viral infection (e.g., hepatitis B, C) or injury-driven chronic inflammation (e.g., cirrhosis from excessive alcohol consumption or obesity-induced steatohepatitis) in the liver. Although HBV and HCV incidence is on the decline, the obesity epidemic has resulted in an increase in the number of new cases of HCC in developed countries including the US. Thus, identifying targetable mediators of liver inflammation and HCC represents an important unmet medical need. Interleukin (IL)-27 is a recently discovered cytokine with immunomodulatory roles in infection and autoimmunity. IL-27R signaling reduces inflammation in murine models of atherosclerosis and experimental encephalomyelitis (EAE), ostensibly by suppressing a pro-inflammatory immune response. These findings led us to speculate that IL-27 might function similarly to limit liver inflammation and halt HCC development. Surprisingly, however, we have discovered that eliminating IL-27R signaling decreases tumor development in a mouse model of HCC, suggesting a new, pro-tumorigenic role in HCC for this otherwise anti-inflammatory cytokine. Here we propose to investigate the mechanism(s) by which IL-27R signaling promotes development of HCC and to test the efficacy of IL-27 blockade as a new therapeutic approach for this malignancy. To do so, we will use IL-27-deficient (Il27ra-/-) mice in an established carcinogen (diethylnitrosamine, or DEN)-induced model of liver cancer. We hypothesize that IL-27R signaling alters the balance between pro- and anti-tumor immune responses in HCC, and will define the cellular mechanisms by which IL-27 mediates these effects. We will elucidate how IL-27R signaling regulates immune cell activation and function during HCC development by integrating an array of genetic modeling, histological, cutting-edge imaging and molecular biological methods. Finally, we will test the efficacy of IL-27 blockade, either alone or in combination with other immunotherapies, as a new therapeutic avenue for HCC. Overall, the proposed research will uncover the role of IL-27R signaling in HCC development. This work has strong translational potential with game-changing ramifications for HCC.

Public Health Relevance

HCC represents a growing healthcare burden with very limited therapeutic options and more than 90% 5-year recurrence rate. We have discovered a new role of the cytokine IL-27 in HCC development, allowing us to put forward the exciting proposition that IL-27R blockade, either alone or in combination with other immunotherapeutic approaches, will represent a new treatment option for this refractory malignancy. In this proposal, we will define the mechanism(s) by which IL-27R mediates its tumorigenic effects in HCC and test the therapeutic feasibility of IL-27 neutralization in this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRB-X (M1))
Program Officer
Mccarthy, Susan A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Research Institute of Fox Chase Cancer Center
United States
Zip Code
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Fatkhullina, A R; Peshkova, I O; Koltsova, E K (2016) The Role of Cytokines in the Development of Atherosclerosis. Biochemistry (Mosc) 81:1358-1370